2018
Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States
Bledsoe T, Park H, Rutter C, Aneja S, Nguyen PL, Yu J. Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States. American Journal Of Clinical Oncology 2018, 41: 1062-1068. PMID: 29521648, DOI: 10.1097/coc.0000000000000423.Peer-Reviewed Original ResearchTreatment modality selectionInsurance statusTreatment modalitiesProstate cancerPrivate insuranceProstate cancer treatment modalitiesMultivariable logistic regression analysisInvasive surgeryModality selectionCancer-directed treatmentD'Amico risk classificationTreatment modality choiceNational Cancer DatabaseLocalized prostate cancerPatient insurance statusExternal beam radiotherapyLogistic regression analysisHealth insurance statusStrongest predictorMen ages 18Cancer treatment modalitiesClinical factorsMultivariable analysisActive surveillanceCancer Database
2017
Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance
Mahal A, Mahal B, Nguyen P, Yu J. Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer 2017, 124: 752-759. PMID: 29084350, DOI: 10.1002/cncr.31106.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityMetastatic diseaseCancer-specific mortalityProstate cancer outcomesOutcomes of patientsMedicaid insuranceEnd Results ProgramReceipt of therapyStage of diseaseAfrican American patientsInsurance statusPrivately insured cohortDefinitive treatmentProstate cancerLocalized CaPResults ProgramPrivate insuranceCAP outcomesCancer outcomesAmerican patientsPatientsProstateRacial disparitiesAssociated with raceAssociated with racial disparitiesOutcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance.
Mahal A, Mahal B, Nguyen P, Yu J. Outcomes for men under 65 with high-risk prostate cancer with Medicaid versus private insurance. Journal Of Clinical Oncology 2017, 35: 198-198. DOI: 10.1200/jco.2017.35.6_suppl.198.Peer-Reviewed Original ResearchProstate cancer-specific mortalityHigh-risk prostate cancerProstate cancerTreatment of high-risk prostate cancerInsurance statusCompeting-risks regression modelsHigh-risk CaPPrivately insured menGray's competing-risks regression modelHigh-risk diseaseCancer-specific mortalityEnd Results ProgramMultivariate logistic regressionMetastatic diseaseNon-black menResults ProgramPrivate insuranceInsured menAfrican American menLogistic regressionMetSOutcomesCancerMenMore-than-additive effect